|
Tuesday, 30 June 2009 09:46 |
|
 Spectrum Pharmaceuticals (Nasdaq: SPPI) has two upcoming dates with regulators in the coming days and months. Here are 17 good reasons why Bayer might seriously consider acquiring Spectrum Pharmaceuticals (Nasdaq: SPPI) at some point in the future. Listed below are 17 ongoing clinical trials for Zevalin. Each trial is sorted by its corresponding completion date. Data source: FDA.
July 2 Zevalin
October 8 Fusilev
Bayer Schering (Bayer) markets Zevalin in Europe and abroad - all countries ex. US. Bayer received approval for Zevalin as a first-line consolidation therapy on April 28, 2008. For details, please refer to my recent article here and here.
2009
|
August
|
Phase 2
|
Fludarabine Plus Zevalin . . .
|
|
September
|
Phase 2
|
Response Study of Zevalin in Patients with DLBCL after 6 cycles of CHOP
|
|
December
|
Phase 3
|
Study Comparing Zevalin Regimen with NO further treatment in DLBCL
Patients who are in Complete Remission after CHOP-R
|
2010
|
January
|
Phase 2
|
Zevalin in Combination with Z-CHOP in Treating Patients with Stage 2-4 DLBCL
|
|
July
|
Phase 2
|
Zevalin + Rituxan Maintenance
Sponsor: University of Wisconsin
|
|
August
|
Phase 2
|
Autologous Stem Cell Transplant with Zevalin + Busulfan
|
|
December
|
Phase 2
|
Chemo followed by Zevalin for Relapsed Mantle Cell Lymphoma
Sponsor: Dana-Faber Cancer Institute
|
2011
|
January
|
Phase 2
|
Safety of Zevalin,
Sponsor: Bayer Schering
|
2012
|
January
|
Phase 2
|
Zevalin Twice in Aggressive NHL
|
|
January
|
Phase 2
|
Safety Study to Evaluate Induction & Consolidation Treatment in Mantle Cell Lymphoma
|
|
June
|
Phase 3
|
Zevalin-BEAM for aggressive lymphoma
Sponsor: Sheba Medical Center
|
|
December
|
Phase 1 / 2
|
Zevalin with Non Myeloablative Allogeneic Stem Cell Transplant in NHL
|
2013
|
April
|
Phase 2
|
Consolidation Treatment with Zevalin after R-CHOP Induction in
High Risk Patients According to FLIPI with fNHL
|
2014
|
June
|
Phase 2
|
Zevalin-BEAM with Autologous Stem Cell
|
|
August
|
Phase 2
|
Zevalin & Simultaneous Application of BEAM High Dose Chemo
|
|
October
|
Phase 2
|
Zevalin First-Line fNHL
Sponsor: Charite University, Berlin, Germany
|
2016
|
December
|
Phase 2
|
R-CHOP in fNHL Patients NOT Previously Treated. Consolidation with Zevalin
versus Maintenance with Rituxan
|
CONCLUSION
Though it is NOT possible to conclude that Bayer will acquire SPPI with any certainty, however, it does seem plausible.
Contributed by Justin M. Hall
Disclosure: Long SPPI BiomedReports is not paid or compensated to report news and developments about publicly traded companies. Full disclosure can be read in the About Us Section
Add this page to your favorite Social Bookmarking websites
          
|
